#### Provided by:



## Abramson Cancer Center Grand Rounds 2025-2026

Proving Progress: Optimizing Evidence-Based Radiation Therapy in GI Cancers - Abramson Cancer Center
Grand Rounds 2025-2026 - 11/19/2025
November 19, 2025
8:00 AM - 9:00 AM

### **Target Audience**

This program has been designed for CLINICAL GENETICS AND GENOMICS (MD), INTERNAL MEDICINE - Hematology, NUCLEAR MEDICINE, INTERNAL MEDICINE - Medical Oncology, RADIATION ONCOLOGY, CLINICAL MOLECULAR GENETICS AND GENOMICS, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology, OBSTETRICS AND GYNECOLOGY - Gynecologic Oncology, PEDIATRICS - Pediatric Hematology-Oncology, SURGERY - Complex General Surgical Oncology

#### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe and define the pathophysiology and etiology of oncologic diseases
- 2 Describe new diagnostic methods for different oncologic diseases.
- 3 Discuss how to formulate and prescribe a management plan for different oncologic diseases.
- 4 Discuss how to assess and grade prognostic information and different oncologic diseases.

### **Session Educational Objectives**

After completing this educational activity, participants should be able to:

- 1 Discuss Why the disconnect between clinical experience and trial results
- 2 Discuss goals of cancer therapy

#### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### **Designation of Credit**

**Physicians**: Penn Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) $^{\text{TM}}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

For more information, please contact
Amelia Anderson
(215) 662-3917
Amelia.Anderson@uphs.upenn.edu

# **Acknowledgement of Commercial Support\***None



#### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
joseph R Carver, MD	Course Director	Nothing to disclose - 11/04/2025
Roger B Cohen, MD	Other Planning Committee Member	Consulting Fee-Actuate   Consulting Fee- Genmab (Relationship has ended)   Consulting Fee-Tasca   Consulting Fee-Ono (Relationship has ended) - 11/03/2025
Patricia Gambino, MSN	Nurse Planner	Nothing to disclose - 07/17/2025
Elizabeth Gilbert, PA-C	Physician Assistant Planner	Nothing to disclose - 11/04/2025
Alison W Loren, MD	Other Planning Committee Member	Nothing to disclose - 07/01/2025
John Plastaras, MD	Other Planning Committee Member	Nothing to disclose - 06/30/2025
NINA SANFORD, MD	Faculty	Nothing to disclose - 11/13/2025
Robert H Vonderheide, MD	Other Planning Committee Member	Nothing to disclose - 07/27/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected